We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division


Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

CerTest VIASURE HLA Celiac RT PCR Kit Enables Rapid Resolution of HLA Haplotypes Associated with Celiac Disease

By LabMedica International staff writers
Posted on 21 Sep 2021
Print article
VIASURE HLA Celiac Real Time PCR Detection Kit
VIASURE HLA Celiac Real Time PCR Detection Kit
CerTest Biotec (Zaragoza, Spain) has developed a simple and ready to use real-time PCR for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens associated with Celiac disease (CD).

CD is an autoimmune disorder triggered by the ingestion of gluten in genetically susceptible individuals. Once thought to be a rare disease, CD diagnoses are increasing with current worldwide prevalence at 1%, with female predominance. The disease can occur at any age, with two peaks of onset - one shortly after weaning with gluten in the first two years of life, and the other in the second or third decades of life with a variety of symptoms/manifestations. This multifaceted clinical presentation leads to several phenotypes, i.e., gastrointestinal, extraintestinal, subclinical, potential, seronegative, non-responsive, and refractory.

As with any other autoimmune disease, CD has a strong hereditary component as testified by its high familial recurrence (~ 10–15%). Genetic susceptibility is associated with two sets of alleles, DQA105 - DQB102 and DQA103 - DQB103:02, which code for class II MHC DQ2 and DQ8 molecules, respectively. Although HLA-DQ2/HLA-DQ8 is frequent among the general population (25-35%), only the 3% of these HLA-compatible individuals will go on to develop CD. Being able to quickly and efficiently determine the status of the DQA and DQB alleles in potential CD patients or risk population could dramatically aide in diagnostic work-ups.

An early diagnosis could prevent the development of a clinically severe CD and for this, an exact individual genetic risk assessment could improve current diagnostic strategies and thus prognosis. Sensitive and specific serological tests have become gradually more important in the diagnostic work-up of CD although duodenal biopsy remains the diagnostic ‘gold standard’. To avoid performing this invasive technique, especially in children with symptoms suggestive of CD with high antibody titers, it has been proposed to replace it with genotyping. In a non-invasive way, identifying and quantifying the risk of developing CD in newborns from affected family members could be useful for programming individualized follow-up timing.

With the aim of contributing to the development of practical algorithm for the diagnosis of CD, CerTest has developed VIASURE HLA Celiac Real Time PCR Detection Kit for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens associated with CD. The kit detects the alleles DQA105, DQB10302, DQB102, DQA102, DQA103 and NO DQB102 in blood samples. DNA is extracted from blood specimens, multiplied using Real Time amplification and detected using specific primers and a fluorescent reporter dye probe for HLA alleles.

Using whole blood clinical samples of patients predisposed to CD, the clinical performance of VIASURE HLA Celiac Real Time PCR Detection Kit was evaluated, verifying that the test is as accurate, sensitive and specific as the assays with similar characteristics already available on the market. Notably, thanks to the product's design and its lyophilized format, handling is minimal and easier than similar molecular assays. These characteristics help the process to be faster, being able to obtain the results and therefore, the clinical diagnosis time in approximately two hours.

Related Links:

CerTest Biotec

Gold Supplier
Hemostasis Analyzer
STA R Max 3
Respiratory Multiplex RT-PCR Kit
Respiratory Multiplex RT-PCR Kit
Cytology Sample Processor
SDSCP9000 CytoPath Processor
Undercounter Laboratory Refrigerator

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.